ACTRN12611000427976CompletedPhase 4
Therapeutic Efficacy Testing For Artemether Lumefantrine in treatment of uncomplicated Plasmodium falciparum malaria in 3 sentinel sites (Katete, Mansa and Chipata) in Zambia
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Ministry of Health
- Enrollment
- 261
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Non-randomised trial
- Primary Purpose
- Treatment
- Masking
- Open (masking not used)
Eligibility Criteria
- Ages
- 6 Months to 60 Years (—)
- Sex
- All
Inclusion Criteria
- •*age equal to or above 6 months excluding female aged 12 to 18 years;
- •*mono-infection with P. falciparum detected by microscopy;
- •*parasitaemia of 1,000 to 200,000/microlitre asexual forms; *presence of axillary equal to or more than 37.5 degrees centigrade or history of fever during the past 24 h;
- •*ability to swallow oral medication;
- •*ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
- •*informed consent from the patient or from a parent or guardian in the case of children.
Exclusion Criteria
- •*presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of World Health Organization (WHO);
- •*mixed or mono-infection with another Plasmodium species detected by microscopy;
- •*presence of severe malnutrition (defined as a child whose growth standard is below 3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference below 110 mm);
- •*presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human Immuno Deficiency Virus /Auto Immune Deficiency Syndrome(HIV/AIDS);
- •*regular medication, which may interfere with antimalarial pharmacokinetics;
- •*history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s);
- •*a positive pregnancy test or breastfeeding;
- •*unable to or unwilling to take contraceptives for pregnancy negative married women of child-bearing age.
Investigators
Similar Trials
Recruiting
Not Applicable
Therapeutic Efficacy Testing of artemether-lumefantrine for the treatment of uncomplicated plasmodium falciparum malaria infection in mainland TanzaniaInfection - Studies of infection and infectious agentsMalariaACTRN12612001092886Ministry of Health of Tanzania352
Recruiting
Not Applicable
Therapeutic efficacy testing of artemether lumefantrine and artesunate+sulfadoxine/pyrimethamine combination therapiesfor the treatment of uncomplicated P. falciparum infections in Mali.Infection - Studies of infection and infectious agentsMalariaACTRN12612001118897Malaria Research and Training Center552
Recruiting
Not Applicable
Therapeutic efficacy study of artemether-lumefantrine and artesunate-amodiaquine in the treatment of uncomplicated Plasmodium falciparum malaria at two sentinel sites in TogoACTRN12612001039875Ministere de la Sante du Togo450
Recruiting
Phase 4
Ethiopia P. vivax and P. falciparum in-vivo Effectiveness Study 2021-22MalariaPACTR202110520435408ICAP at Columbia University402
Completed
Unknown
Efficacy of antimalaria drug for the treatment of malariaMalariaPACTR202309773069812niversity of Gondar88
